Australia's most trusted
source of pharma news
Thursday, 11 September 2025
Posted 10 September 2025 PM
A Federal Court judge has rebuffed Bayer's bid for an interlocutory injunction against Sandoz launching an Eylea biosimilar.
Sandoz has two biosimilars that reference Eylea registered on the ARTG, Afqlir and Enzeevu, landing a few months after Celltrion's Eydenzelt. However, Sandoz received a recommendation for Afqlir/Enzeevu from the PBAC at its July meeting.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.